+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Melanoma Inhibiting Activity A new prognostic serum marker in patients with malignant melanoma



Melanoma Inhibiting Activity A new prognostic serum marker in patients with malignant melanoma



Clinical Chemistry & Laboratory Medicine 37(SPEC Suppl. ): S226




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035279158

Download citation: RISBibTeXText


Related references

Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Research 57(15): 3149-3153, 1997

Prognostic significance of melanoma inhibiting activity levels in malignant melanoma. Melanoma Research 11(6): 627-632, 2001

Evaluation of serum YKL-40 as a prognostic marker for overall survival in patients with metastatic malignant melanoma. Journal of Clinical Oncology 23(16_Suppl): 7520-7520, 2016

Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients. Cytokines, Cellular and Molecular Therapy 7(2): 71-74, 2003

Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma. Melanoma Research 19(1): 17-23, 2009

Serum S-100B A prognostic marker in malignant melanoma. Tumor Biology 23(Suppl. 1): 31, 2002

Serum S100beta protein as a marker of disease activity in patients with malignant melanoma. Medical Oncology 18(2): 109-120, 2002

The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma. Medical Oncology 22(3): 241-246, 2005

Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa. Melanoma Research 12(4): 319-323, 2002

Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. Journal of Clinical Oncology 19(3): 824-831, 2001

Diagnostic sensitivity of S-100 protein and melanoma-inhibiting activity in the follow-up care of a malignant melanoma. Anticancer Research 19(6D): 5712, 1999

Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres Dans les Recherches sur le Cancer 158: 158-168, 2000

S-100B and MIA (melanoma inhibiting activity) serum proteins: a prospective study of their value as melanoma progression markers. Annales de Dermatologie et de Venereologie 129(5 Pt 1): 739-740, 2002

Tyrosinase activity in three types of the malignant melanoma: Superficial spreading melanoma, mentigo maligna melanoma and Nodular Melanoma. Archives of Dermatological Research 252(3): 193-201, 1975

Tyrosinase activity in three types of the malignant melanoma: superficial spreading melanoma, lentigo maligna melanoma and nodular melanoma. Archiv für Dermatologische Forschung 252(3): 193-201, 1975